David Goel’s Pacira BioSciences PCRX Stock Holding History

David Goel’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-519,703	Closed	-$36.8M	–	20
2015 Q2	$36.8M	Buy	519,703 +19,703	+4%	+$1.55M	1.64%	18
2015 Q1	$44.4M	Buy	500,000 +150,000	+43%	+$15.2M	2.28%	17
2014 Q4	$31M	Buy	+350,000	New	+$33.1M	1.64%	15

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

HCM

Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Goel's PCRX Position: Q3 2015 in Review

David Goel sold out of Pacira BioSciences (PCRX) in Q3 2015, closing a stake of 519,703 shares — an estimated $36.8M sold.

David Goel first reported a position in PCRX in Q4 2014 and held it in 3 quarters. The position peaked at $44.4M in Q1 2015. 177 funds tracked by Wall St. Rank hold PCRX as of Q3 2015.

David Goel reported no remaining Pacira BioSciences position as of Q3 2015 after selling out during the quarter.
David Goel sold 519,703 Pacira BioSciences shares in Q3 2015, an estimated $36.8M.
David Goel first reported a position in Pacira BioSciences in Q4 2014 and held it in 3 quarters.
David Goel's Pacira BioSciences position peaked at $44.4M in Q1 2015.
177 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2015.

Based on Matrix Capital Management Company's 13F filing for Q3 2015, filed 16 Nov 2015.